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Abstract
Alzheimer’s disease (AD) is tightly correlated with synapse loss in vulnerable brain regions.
It is assumed that specific molecular entities such as Aβ and tau cause synapse loss in AD,
yet unbiased screens for synaptotoxic activities have not been performed. Here, we per-
formed size exclusion chromatography on soluble human brain homogenates from AD
cases, high pathology non-demented controls, and low pathology age-matched controls
using our novel high content primary cultured neuron-based screening assay. Both presyn-
aptic and postsynaptic toxicities were elevated in homogenates from AD cases and high
pathology non-demented controls to a similar extent, with more modest synaptotoxic activi-
ties in homogenates from low pathology normal controls. Surprisingly, synaptotoxic activi-
ties were found in size fractions peaking between the 17–44 kDa size standards that did not
match well with Aβ and tau immunoreactive species in these homogenates. The fractions
containing previously identified high molecular weight soluble amyloid beta aggregates/
”oligomers” were non-toxic in this assay. Furthermore, immunodepletion of Aβ and tau did
not reduce synaptotoxic activity. This result contrasts with previous findings involving the
same methods applied to 3xTg-AD mouse brain extracts. The nature of the synaptotoxic
species has not been identified. Overall, our data indicates one or more potential Aβ and tau
independent synaptotoxic activities in human AD brain homogenates. This result aligns well
with the key role of synaptic loss in the early cognitive decline and may provide new insight
into AD pathophysiology.
Introduction
Alzheimer disease (AD) is a progressive, neurodegenerative condition characterized by a pro-
longed decline in cognitive abilities. It is the most prevalent late-life cognitive disease that
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affects an estimated 6.2 million Americans in 2021. The pathological hallmarks of AD are
extracellular senile plaques (SP) which contain abundant amyloid-beta (Aβ) and intracellular
neurofibrillary tangles (NFT) characterized by hyperphosphorylated tau protein. However,
accumulated evidence suggests that SP and NFT are not limited to patients with AD but are
also present in the brains of cognitively normal elders [1, 2]. In fact, many individuals are able
to remain cognitively normal and endure high SP loads for decades [3, 4]. Exploring the char-
acteristics of such individuals compared to those AD patients who had been clinically and
histopathologically diagnosed is the subject of much recent interest [5–10], and may be of
great importance for understanding AD pathogenesis. We and others have found that soluble
Aβ aggregate/”oligomer” concentrations in demented AD cases are higher and more tightly
correlated with Aβ plaque coverage compared with non-demented individuals with AD
pathology [11]. Furthermore, significantly lower total Zn2+ levels and no detectable association
of Aβ oligomers with post-synaptic terminals are found in these individuals [12]. On the other
hand, Aβ42 monomer levels are higher in these cognitively normal individuals than in AD
cases [13]. To date, the mechanisms underlying the apparent dissociation between clinical
impairment and AD pathology remain unknown; it is possible that these asymptomatic indi-
viduals may possess ‘resilient’ factors or have substantial cognitive ‘reserve capacity’ that pre-
vents progression of clinical impairment [14, 15]. It is also possible that they are merely at the
initial, ‘preclinical’ stage of AD [10], or that these hallmark pathologies are truly dissociated
from the clinical syndrome [16].
First described by Gonatas [17], there have been numerous studies demonstrating that AD
is tightly correlated with synapse loss in vulnerable brain regions [18, 19], which has led to the
hypothesis that loss of synapses is a key event in early cognitive decline. While the mechanism
of synapse loss in AD is not fully understood, it is presumed that specific molecular entities,
such as Aβ and tau are responsible for synaptic degeneration [20–22]. Unbiased screens, how-
ever, have not been performed. Evaluation of the nature of neuronal and synaptic changes in
cognitively normal individuals with AD pathology and in AD cases may provide an advantage
for identification of synaptotoxic substances and for understanding of the progression AD.
We recently developed a robust high-content imaging method for assessing synaptic changes
in a 96 well plate format [23]. Our method uses serial imaging of endogenous labeled presyn-
aptic VAMP2-mRFP [24] and postsynaptic PSD95-mVenus [25] protein in long-term cultured
murine primary neurons to quantitate the number of synaptic puncta for the assessment of
synaptic changes (Fig 1). We previously showed that multiple synaptotoxic activities can be
detected in size-exclusion chromatography (SEC) fractioned brain homogenates from 3xTg-
AD mice [26]. Interestingly, both Aβ-related and apparently Aβ-independent synaptotoxic
activities have been identified [23]. However, the synaptotoxicities in human brain homoge-
nates have not been assessed in this fashion.
In an attempt to understanding the differences between AD pathology positive non-
demented individuals and clinically affected AD cases, in this study we screened for synapto-
toxic activities in SEC fractioned brain homogenates from a total of 29 individuals. In addition,
we evaluated the role of Aβ and tau in synaptotoxic SEC fraction by immunodepletion.
Materials and methods
Human frontal cortical brain samples
Human frontal cortical tissue samples (n = 29) were obtained from the Charles F. and Joanne
Knight Alzheimer’s Disease Research Center at Washington University School of Medicine in
Saint Louis. Cognitive status was evaluated with a validated retrospective postmortem inter-
view with an informant to establish the Clinical Dementia Rating (CDR). Cognitively normal
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subjects (CDR0), cognitively normal subjects with AD pathology (CDR0+), mildly demented
subjects (CDR1), and severe demented subjects (CDR3) were used in this study (Table 1).
Homogenization of brain tissue and immunodepletion of Aβ and tau
Approximately 200 mg of frozen human frontal cortical tissue was weighed and placed into
ice-cold ‘Neurobasal Salt’ solution (homemade buffer containing all inorganic salts, D-Glu-
cose, HEPES, and Sodium Pyruvate of Neurobasal medium) containing 1X protease inhibitor
cocktail (Sigma-Aldrich) at 200 mg/mL and homogenized using a Dounce tissue grinder on
ice as described before [27]. After centrifugation at 21,000 xg for 45 min at 4˚C, the top 90% of
supernatant was collected. Protein concentration was assessed with the Micro BCA Protein
Assay Kit (ThermoFisher).
Immunodepletion of Aβ and tau was performed using 150 μg of total protein from soluble
fraction of tissue homogenates. Five micrograms of each HJ3.4 and HJ5.1 (for Aβ) [28, 29] and
HJ8.7 (anti-tau118-122 AAGHV) and HJ9.3 (anti-tau589-598 GGKVQIINKK) antibodies [30]
were added and incubated at 4˚C for 1 hour. Thirty microliters of BSA blocked Protein G
PLUS-Agarose (Santa Cruz) was added to the sample and incubated at 4˚C overnight on a
rotator. Samples were then centrifuged at 3,000 xg for 5min at 4˚C. The immunodepleted
supernatant was collected.
Size exclusion chromatography
One hundred fifty micrograms of total protein was injected into a 1 mL sample loop and sepa-
rated on a Superdex 200 10/300 GL column eluted with 35 mL of ‘Neurobasal Salt’ solution
Fig 1. Schematic of the assessment of synaptic changes using the high-content imaging system. (A, B)
Hippocampal neurons from genetically modified mice with fluorescent synapses were isolated and cultured in treated
96-well microplates for more than 20 days in vitro (DIV); (C-F) Human frontal cortex homogenates from control and
AD samples were separated by size exclusion chromatography (SEC) and added to individual wells of 96 well plates;
(G) Synapses were imaged before and after the addition of fractionated human brain samples using the ImageXpress
high-content screening system equipped with environmental control unit for live cell imaging; (H) Pre-synaptic
VAMP2-mRFP puncta, post-synaptic PSD95-mVenus puncta, and colocalized puncta were analyzed; (I) Heat map
analysis showed synaptotoxic activities in SEC fractions from control and AD human samples at 24 and 72 hours;
significant loss of colocalized synaptic puncta was identified in neurons exposed to low molecular weight (F17-20)
fractions.
https://doi.org/10.1371/journal.pone.0259335.g001
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supplemented with 1X Pen-Strep at a flow rate of 0.8 mL/min using an AKTA Purifier FPLC.
Twenty-Eight 1 ml fractions that covered the entire UV 280 positive eluent were collected and
stored at 4˚C. All samples were tested within 2 days, and the rest were stored at -80˚C for fur-
ther analysis.
Measurement of soluble Aβ1–40, 1–42, and oligomeric Aβ using sandwich
ELISA
The amount of total Aβ and oligomeric Aβ were evaluated by sandwich ELISA as described
previously [27]. In brief, 100 μL of an anti-Aβ HJ3.4 (for oligomeric Aβ) or HJ2 (for total Aβ1–
40) and HJ7.4 (for total Aβ1–42) antibody was coated to 96-well Nunc MaxiSorp flat-bottom
plates (ThermoFisher) at 20 μg/mL in carbonate buffer overnight and then blocked with 2%
BSA in PBS for 1 hour at room temperature. Samples and standard were loaded and incubated
overnight; 6M guanidine-HCl was added at 5% of total sample volume for the total Aβ mea-
surement to prevent oligomerization during the incubation. Biotinylated HJ3.4 antibody in
PBS at 100 ng/mL was used as detection antibody and incubated at room temperature for 1
hour for the measurement of both total and oligomeric Aβ. Poly-streptavidin HRP-20
Table 1. Characteristics of human brain frontal cortex samples.
Sample ID Gender Age, yrs Clinical Dementia Rating Postmortem Interval, hrs
1 Male 89.6 CDR0 21.8
2 Female 72.1 CDR0 15.0
3 Male 91.1 CDR0 8.5
4 Male 97.0 CDR0+path 3.5
5 Female 91.7 CDR0+path 12.0
6 Female 100.9 CDR0+path 21.0
7 Female 95.4 CDR0+path 23.0
8 Male 80.8 CDR0+path 5.5
9 Female 76.7 CDR0+path 5.0
10 Female 86.4 CDR1 6.7
11 Female 89.0 CDR1 19.0
12 Female 92.7 CDR1 23.0
13 Female 94.2 CDR1 11.6
14 Female 104.4 CDR1 19.0
15 Male 68.6 CDR1 21.0
16 Female 86.0 CDR1 18.0
17 Female 81.0 CDR1 21.0
18 Male 72.7 CDR1 4.5
19 Female 76.8 CDR1 17.0
20 Male 64.6 CDR3 11.0
21 Male 75.1 CDR3 4.0
22 Male 85.9 CDR3 10.0
23 Female 80.8 CDR3 5.15
24 Female 85.8 CDR3 20.0
25 Male 80.6 CDR3 13.5
26 Male 71.6 CDR3 7.0
27 Male 81.0 CDR3 5.25
28 Male 86.6 CDR3 12.0
29 Female 81.5 CDR3 7.5
https://doi.org/10.1371/journal.pone.0259335.t001
PLOS ONE High-content screening reveals synaptotoxic activities in Alzheimer patients and high-pathology controls
PLOS ONE | https://doi.org/10.1371/journal.pone.0259335 November 8, 2021 4 / 19
(Fitzgerald) in PBS at 30 ng/mL was then added and incubated for 30 min at room tempera-
ture. After final wash, the assay was developed by adding 100 μL of 3,30,5,50-Tetramethylbenzi-
dine (TMB) (Sigma-Aldrich) and the absorbance was read on a Synergy 2 plate reader
(BioTek) at 650 nm.
Measurement of total tau and phosphorylated tau (T181) using sandwich
ELISA
The amount of total tau and phosphorylated tau (T181) were evaluated by sandwich ELISA
using commercially available kits (ThermoFisher) following the manufacture instructions. In
brief, 100 μL of samples and standards were loaded onto precoated plates and incubated over-
night. After washing, 100 μL of biotinylated antibody Hu Tau (total) biotin conjugated solu-
tion was added and incubated for 2 hours at room temperature followed by incubation of 1X
Streptavidin-HRP solution. After final washing, 100 μL of TMB was added and incubated for
30 minutes and the absorbance was read on a Synergy 2 plate reader (BioTek) at 650 nm. For
phosphorylated tau (T181), the same procedure was used except 50 μL of antibody Hu Tau
(pT181) and anti-rabbit IgG HRP was used.
Measurement of A11 immunoreactive oligomer, total tau, and
phosphorylated tau using indirect ELISA
The amount of A11 immunoreactive oligomer, total tau, and phosphorylated tau were also
measured by indirect ELISA. In brief, 100 μL of total protein was coated to 96-well Nunc Max-
iSorp flat-bottom plates at 20 μg/mL in sample buffer overnight at 4˚C. Plate was then washed
and blocked with 4% BSA for 1 hour at room temperature. One hundred micro-liters of anti-
Oligomer A11 antibody (for Aβ and other oligomeric structure, ThermoFisher), HJ8.7 (anti-
tau118-122), HJ9.3 (anti-tau589-598) [30], or anti-tau phospho T205 (for phosphorylated tau
T205, Abcam) was added to the well at 1 μg/mL and incubated at 4˚C overnight with shaking.
After wash, HRP conjugated anti-mouse or anti-rabbit antibody (Cell Signaling Technolgies)
was added to the well at 1:1000 dilution and incubated at room temperature for 2 hours with
shaking. After final wash, the assay was developed by adding 100 μL of TMB (Sigma-Aldrich)
and the absorbance was read on a Synergy 2 plate reader (BioTek) at 650 nm.
Long-term primary neuron culture in 96-well microplates
All cell culture procedures were performed under standard aseptic working conditions.
Ninety-six well glass bottom plates (Cellvis) were coated with 50 μg/mL Poly-D-lysine (PDL)
(Sigma-Aldrich) at 50 μL per well at room temperature overnight. Plates were then washed
with sterile distilled water three times and dried for at least 30 min before use. Hippocampal
neurons were collected and cultured as described [23]. To minimize evaporation and edge
effects on the microplate during imaging, the interwell region of the culture plate was filled
with sterile water. Following 2 days in vitro (DIV), 50 μL of plating medium with 5 mM Cyto-
sine β-D-arabinofuranoside (Ara-C) was added to the wells. At DIV 5, 50% of medium was
replaced with maintenance medium containing 1X B27 Plus in Neurobasal Plus medium
(ThermoFisher) with 100mM GlutaMAX. Thereafter, 50% of medium was replaced with fresh
maintenance medium every 4 to 5 days for up to 30 days.
Live primary neuron based high-content screening of synaptic activity
Live primary neuron based 96-well plate high-content screening was performed using MetaX-
press High-Content Image Acquisition and Analysis Software 6.1 and ImageXpress Micro XLS
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Wide-field High-Content Analysis System equipped with temperature and CO2 environmental
control units (Molecular Devices) and X-Cite 110LED white light LED light source (Excelitas)
at 32 ± 2˚C with 5% CO2. Images were taken with a Nikon 60X CFI Super Plan Fluor ELWD
objective. For all samples, triplicated measurements were performed (n = 3 wells per SEC frac-
tion). Five images per well were obtained by taking five horizontally adjacent imaging sites
near the center of the well. Laser-based autofocusing methods on both plate bottom and well
bottom were used. Exposure times of 400 ms and 1200 ms were used for VAMP2-mRFP and
PSD95-mVenus respectively. To assess synapses in live primary neurons, cells were cultured
for 21 days, then the baseline scans were performed at DIV 22. Potentially synaptotoxic sub-
stances were then added, and the same regions of each well were imaged twice. For these
experiments, the second and third scans were performed 24 and 72 hours later to evaluate the
acute to short-term effects of the treatments.
Semi-automatic image analysis using Fiji/ImageJ and MetaXpress
Synaptic density was assessed by analyzing the total number of presynaptic (VAMP2-mRFP)
puncta, postsynaptic (PSD95-mVenus) puncta, and colocalized puncta for each image. Images
taken at different time points were semi-automatically aligned, processed, and analyzed using
MetaXpress 6.1 and Fiji/ImageJ (V1.52n). All images were processed and analyzed automati-
cally using macros with batch processing in Fiji/ImageJ and batch processing ‘journal’ function
in MetaXpress 6.1. First, time-lapse images from the same image site taken at different time
points were automatically aligned using MetaXpress. Overlapped regions of interest (ROI)
from images taken at different time points were processed automatically using a batch process
‘journal’ including steps of Flatten background using fluorescent light (pixel size = 5), 2D
Deconvolution using Nearest Neighbors method (Filter size = 10, Scaling factor = 0.97, Sup-
press noise checked), and Morphology Filters using Top-hat method (Area = 50 pixels2). All
images were then processed automatically using a batch process macro in ImageJ including
steps of AutoThreshold with MaxEntropy, filtered with medium method. Finally, the total
number of synaptic puncta from each processed image were automatically counted using the
‘Analyze Particles’ function in Fiji/ImageJ. Particles between 2 and 50 voxels in size were
counted. Last, to analyze colocalized synaptic puncta, processed VAMP2 and PSD95 images
from step two were merged using ImageJ macro ‘Batch RG Merge’, and the merged images
were analyzed automatically using batch process ‘Synapse Counter’ ImageJ Plugin [31] with
0.1 and 0.2 for ‘Rolling ball radius’ and ‘Maximum filter radius’, ‘Otsu’ for ‘Method for thresh-
old adjustment’, and 2 to 50 voxel size was used for both pre- and postsynaptic particle size.
Statistical analysis
All data were analyzed with Fiji/ImageJ, and statistical analysis was performed with Prism 7.0
(GraphPad Software). The total number of counted synaptic puncta from different time points
were normalized to percentage baseline puncta number. The sample size for statistical analyses
was the number of individual human brain specimens in each group. One-way ANOVA fol-
lowed by Tukey’s multiple comparisons test was used for ELISA analysis among all sample
groups. Two-way ANOVA followed by Dunnett’s multiple comparisons test was used to com-
pare synapse loss in CDR0+, CDR1, and CDR3 sample groups with control CDR0 group, as
well as to compare synapse loss in immunoprecipitated sample groups with no treatment con-
trol group. Two-way ANOVA followed by Tukey’s multiple comparisons test was used to com-
pare synapse loss among all sample groups. A P-value� 0.05 was considered statistically
significant.
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Results
Characterization of study subjects
Fresh frozen frontal cortical tissue from 29 human subjects were used in this study, including
cognitively normal subjects with no AD pathology (‘CDR0’: mean age = 84.2 ± 8.6 years, post-
mortem interval (PMI) = 15.1 ± 5.4 hours), cognitively normal subjects with Alzheimer’s
pathology (‘CDR0+’: mean age = 90.4 ± 8.8 years, PMI = 11.7 ± 7.8 hours), mildly demented
Alzheimer’s cases (‘CDR1’: mean age = 85.2 ± 10.2 years, PMI = 16.0 ± 6.0 hours), and severely
demented Alzheimer’s cases (‘CDR3’: mean age = 79.4 ± 6.7 years, PMI = 9.5 ± 4.6 hours)
(Table 1). All samples were obtained from the Charles F. and Joanne Knight Alzheimer Disease
Research Center at Washington University in St Louis.
Comparison of Aβ and tau levels in brain homogenates indicates
differences among CDR0, CDR0+, and AD patients
We and others have demonstrated previously that the level of Aβ oligomers is tightly correlated
with Aβ plaque coverage and higher in CDR1 patients than CDR0+ AD pathology controls
[11]. In this study, we assessed the levels of several Aβ and tau species in soluble brain homoge-
nates from all study subjects. The level of total soluble Aβ1–40 and Aβ1–42 in aqueous sample
buffer was assessed by a highly sensitive ELISA assay [11]. Among all sample groups, Aβ1–40
showed no statistical difference (F(3,25) = 1.289, p = 0.2998) (Fig 2A), whereas Aβ1–42 levels in
AD patients were significantly lower than CDR0 normal controls (Fig 2B) by one-way
ANOVA (F(3,25) = 5.293, p = 0.0058) followed by Tukey’s multiple comparison test (CDR0 vs
CDR1: p = 0.016 and CDR0 vs CDR3: p = 0.0078). These findings indicated the expected cor-
respondence of soluble Aβ1–42 level and AD progression [32]. The level of Aβ1–42 in CDR0
+ samples was intermediate. The level of soluble Aβ aggregates in aqueous sample buffer was
assessed by our previously established sandwich [11]. There were significant differences
between groups by one-way ANOVA (F(3,25) = 5.663, p = 0.0042). All subjects with AD
pathology, including CDR0+, showed significantly higher levels of Aβ oligomers than normal
controls (CDR0+: p = 0.0021, CDR1: p = 0.0352, and CDR3: p = 0.0156) (Fig 2C). In contrast,
indirect ELISA using the A11 anti-oligomer antibody [33] revealed a trend towards higher
level of A11 immunoreactivity in CDR1 and CDR3 subjects, but without a statistical difference
between groups (F(3,25) = 0.8219, p = 0.4941) (Fig 2D). The level of total soluble tau and phos-
phorylated tau (T181) in aqueous sample buffer from all subjects was similarly compared.
Total tau was significantly different between groups (F(3,25) = 4.412, p = 0.0127) with lower
level of total tau in the CDR0 group compared with the CDR3 group (p = 0.0101) (Fig 2E).
Phosphorylated T181 tau showed no significant difference between groups (F(3,25) = 2.078, p
= 0.1287) (Fig 2F). Interestingly, indirect ELISA using the HJ8.7 (anti-tau118-122 AAGHV)
antibody [30] revealed significantly higher tau in CDR0 group compared with all AD pathol-
ogy positive samples (F(3,25) = 3.751, p = 0.0237; CDR0 vs CDR0+: p = 0.0484, CDR0 vs
CDR1: p = 0.0005, and CDR0 vs CDR3: p = 0.0002) (S1 Fig) while no difference was found
when using the HJ9.3 (anti-tau589-598 GGKVQIINKK) antibody [30] (F(3,25) = 1.004, p =
0.4075; S1 Fig). In addition, indirect ELISA using an anti-phosphorylated tau (phospho T205)
antibody revealed a significantly higher level in the CDR0 group compared with CDR1 (F
(3,25) = 3.448, p = 0.0318; CDR0 vs CDR1: p = 0.0408) (S1 Fig).
Aβ and tau in soluble lysates migrate at multiple sizes in SEC fractions
To understand synaptotoxic activity in SEC fractions, we first measured the level of total
Aβ, oligomeric Aβ, tau, total protein, and salt concentration in samples, which may
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independently cause synapse loss in our assay (Fig 3). Total protein concentration from each
fraction was evaluated by UV280 measurement. Most proteins eluted in fractions 14 to 17
mL, 20 to 22 mL, and 23 to 25 mL. The concentration of total salt was estimated by conduc-
tivity measurement. The level of total salt in all collected fractions were nearly identical (Fig
3A). Total Aβ and oligomeric Aβ level in each SEC fraction were assessed by sandwich
ELISA. For total Aβ, two major peaks were present centered at 6 to 9 mL (high molecular
weight) and 18 to 21 mL (low molecular weight) of total eluent with estimated molecular
weights of larger than 670 kDa and slightly higher than 1.35 kDa. Very low levels of Aβ, close
to the detection limit, were distributed between the two peaks (Fig 3B) [34]. For oligomeric
Aβ, high molecular weight Aβ oligomer (MW� 670 kDa) was detected in Fractions 6 to 9,
no other major peak was identified (Fig 3C). The level of total tau was assessed by indirect
ELISA. Tau immunoreactivity was distributed widely from Fraction 9 to 22. The highest
amount of tau was found in the 16–17 mL fractions, with an estimated molecular weight in
the 44 kDa range (Fig 3D).
Fig 2. Scatterplots of individual levels of Aβ and tau in brain homogenates from control and AD cases. All samples
were measured in triplicate. One-way ANOVA followed by Tukey’s multiple comparisons test were used for all
measurements (��� p� 0.001, �� p� 0.01, � p� 0.05, error bar indicates SEM). (A) The levels of Aβ1–40 did not differ
among sample groups; (B) The level of Aβ1–42 in the CDR0 group was significantly higher in than in the CDR1 group
(p = 0.016) and CDR3 group (p = 0.0078); (C) The level of Aβ oligomer measured by sandwich ELISA in CDR0 group
was significantly lower than CDR0+ (p = 0.0021), CDR1 (p = 0.0352), and CDR3 (p = 0.0156) groups; (D) The levels of
A11 positive oligomer measured by indirect ELISA did not significantly differ between groups; (E) The level of total
tau was significantly lower in the CDR0 group than in the CDR3 group (p = 0.0101); (F) The levels of T181
phosphorylated tau did not significantly differ between groups.
https://doi.org/10.1371/journal.pone.0259335.g002
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HCS screening reveals synaptotoxic activities in low molecular weight SEC
fractions
Interestingly, synaptotoxic activities were identified in all samples including CDR0 normal
controls (Figs 1I and 4). Human brain SEC fractions that showed synaptotoxic activities were
distributed from 17 to 20 mL of the total SEC eluent, which indicates larger molecular weight
components than the synaptotoxic fractions identified in 3xTg-AD mouse brain lysates
assessed under identical conditions (fractions 20–22) [23]. Furthermore, the fractions with
synaptic toxicity were slightly larger than those containing Aβ monomer (fractions 18–21, Fig
3B), and smaller than the peak of the tau distribution (fractions 16–17, Fig 3C). The fractions
with synaptic toxicity had relatively low total protein concentrations and similar conductivity
(Fig 3A) relative to other non-synaptotoxic fractions from the same brains.
SEC fractions from CDR0+ and CDR1 brains showed the most severe
synaptotoxic activities while fractions from CDR0 brains showed the
mildest synapse loss
HCS screening was performed on samples from a total of 29 subjects across four groups. Sur-
prisingly, all four groups including CDR0 contained synaptotoxic activities in low molecular
weight fractions (Figs 1I, 4 and 5, S2 and S3 Figs). However, the level of presynaptic VAMP2
loss in wells incubated for 72 hours with fractions from AD pathology positive samples (CDR0
Fig 3. Representative SEC profile of total protein, conductivity, total Aβ level, oligomeric Aβ level, and total tau
levels from a CDR3 patient. Total protein and conductivity were measured by UV detector (mAu) and conductivity
detector (mS/cm); the levels of total Aβ, oligomeric Aβ, and tau in each fraction were measured by ELISA. (A) SEC
elution profile of total protein and conductivity; (B) High molecular weight Aβ aggregates/oligomers (MW� 670 kDa)
was detected in Fractions 6 to 9; low molecular weight Aβ (MW� 17 and� 1.35 kDa) was detected in Fractions 18 to
22; no other major peak was measured in other fractions, however, very low signals just above the lower detection limit
(dashed line) were identified in intermediate fractions; (C) High molecular weight Aβ aggregates/oligomer
(MW� 670 kDa) was detected in Fractions 6 to 9, no other major peak was measured in the other fractions; (D) Total
tau was detected in Fractions 9 to 22; the largest level of total tau was detected in Fractions 16 to 17 with an estimated
MW around 44 kDa.
https://doi.org/10.1371/journal.pone.0259335.g003
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Fig 4. Heatmaps of synaptotoxic activities in each SEC fractions from control and AD case groups at 72 hours.
Scatterplots of synaptotoxic activities of each individual subject is shown in S3 Fig. (A) Comparison of presynaptic
VAMP2 synaptotoxic activities among control and AD case groups at 72 hours; significant VAMP2 loss were found in
wells incubated with lysate fractions 17 to 20; several fractions from CDR0+ and CDR1 showed statistically more
VAMP2 loss than from CDR0; (B) Comparison of postsynaptic PSD95 synaptotoxic activities among control and AD
case groups at 72 hours. Loss of PSD95 post synaptic puncta was found in wells incubated with lysate fractions 17 to
20. Fraction 18 from CDR0+ and CDR1 brain homogenates caused more PSD95 postsynapse loss than fraction 18
from CDR0 brains. Fraction 19 from CDR3 brain homogenates caused more PSD95 postsynapse loss than fraction 19
from CDR brains. (C) Comparison of colocalized pre and post synaptic puncta among control and AD case groups at
72 hours; loss of colocalized synaptic puncta were found in wells incubated with fractions 17 to 20. Fractions 17–19
from CDR0+ and CDR1 brain homogenates caused more colocalized synaptic puncta loss than comparable fractions
from CDR0 brains.
https://doi.org/10.1371/journal.pone.0259335.g004
Fig 5. Representative images of PSD95 changes at baseline (00 hr) and after 72 hours incubation with homogenate
Fraction 18 from CDR0, CDR0+, CDR1, and CDR3 groups. Mild loss of PSD95 was observed in CDR0 group, while
severe loss of PSD95 was observed in CDR0+ and CDR1 groups. Scale bar = 50 μm.
https://doi.org/10.1371/journal.pone.0259335.g005
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+, CDR1, and CDR3) were significantly higher than CDR0 samples by Dunnett’s multiple
comparisons test (Fig 4A). CDR1 samples lysate fractions induced the most severe loss, fol-
lowed by CDR0+ sample lysate fractions. Similar trends were observed in loss of postsynaptic
PSD95, though most postsynaptic changes were not statistically significant by Dunnett’s multi-
ple comparison tests (Figs 4B and 5). The loss of colocalized pre- and post-synaptic puncta was
similar to the level of presynaptic VAMP2 loss: significant loss of colocalized pre and postsyn-
aptic structures were identified only in fractions that caused significant pre and post synapse
loss individually (F17 to F20) (Fig 4C). Similar results were obtained after 24 hours of exposure
(S2 Fig). The detailed results of statistical comparison between sample groups using two-way
ANOVA followed by Tukey’s multiple comparisons test have been presented in S1 and S2
Tables.
Immunodepletion of Aβ and tau fails to rescue synapse loss
We previously demonstrated that immunodepletion of Aβ from 3xTg-AD mouse brain lysates
partially rescues synapse loss. Although not fully prevented by Aβ removal, these results indi-
cate that some synapse loss is Aβ-dependent in this model. We find that the synaptotoxic activ-
ities in SEC separated human brain homogenates are both slightly larger than those in murine
samples and larger than Aβ monomers. Interestingly, the most synaptotoxic fractions were
among those with the highest tau concentrations, but tau levels were not well-correlated with
synaptotoxic activity in that other fractions with high tau levels were not synaptotoxic. To
assess whether synaptotoxic activities in human brain lysates are associated with Aβ or tau, we
immunodepleted Aβ using HJ3.4 and HJ5.1 antibodies and separately immunodepleted tau
using HJ8.7 and HJ9.3 antibodies followed by SEC separation of CDR0+ and CDR1 samples
(n = 3 for each group). Almost all immunoreactive tau and Aβ were removed by immunode-
pletion as evaluated by ELISA (Fig 6A and 6B). The synaptic activities from fractions 16 to 21
were compared before and after the immunodepletions. Surprisingly, no significant differ-
ences were identified among control and depleted within factions 16–21 except for F20 with
respect to tau depletion (Two-way ANOVA: F(10,90) = 0.5277, p = 0.8664; Dunnett’s multiple
comparisons test for F20: p = 0.0145, Fig 6C, S3 Table). Taken together, these results suggest
that synaptotoxic activities in human brain lysates are Aβ and tau independent.
Correlation of age and post-mortem interval with synaptotoxic activity
To determine whether synaptotoxic activities are related to age or post-mortem interval of the
subjects, Pearson correlation coefficients between age and post-mortem interval vs. averaged
percentage loss of colocalized synaptic puncta were calculated. Neither the age of subjects (R2
= 0.0430 and p = 0.2804) nor the post-mortem interval of the subjects (R2 = 0.0436 and
p = 0.2770) were significantly correlated with synaptotoxic activities (S4 Fig).
Discussion
AD is a slowly progressive neurodegenerative disease characterized by aggregation of Aβ and
tau. Although the pathophysiological roles of Aβ and tau have been widely explored, the patho-
genesis of AD remains inadequately understood. Evidence demonstrates that synapse loss,
rather than Aβ plaques, NFTs, or neuronal loss, is most tightly correlated to dementia in AD
[18, 35]. Numerous studies demonstrated that many individuals are able to remain cognitively
normal in the presence of Aβ plaques [3, 4]. In an attempt to understand the relationship
between synaptotoxicity and Aβ, we performed an unbiased screen for synaptotoxic activities
in the brain homogenates from normal, normal with AD pathology, and AD subjects. We
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found synaptotoxic activities in brain homogenates that did not appear to be related to either
Aβ or tau.
Using our recently developed HCS assay, we compared the synaptotoxic activities in SEC
separated human frontal cortex homogenates from 29 individuals. Synaptotoxic activities were
identified in low molecular weight SEC fractions from all individuals. Remarkably, this effect
was not only observed in CDR1 and CDR3 AD patients, but also CDR0+ and CDR0 non-
demented controls. Furthermore, samples from CDR0+ and CDR1 groups exhibited the most
severe synapse loss, outpacing even CDR3 AD patients. This finding suggests that such synap-
totoxic factors are present before clinical dementia, consistent with the earl onset of synapse
loss in AD [35]. Synaptotoxic activities were also present in CDR0 normal controls, though the
effects were smaller. This potentially reveals a synaptotoxic environment that also develops
with healthy aging, albeit with reduced activity. Alternatively, it is possible that, individuals in
the CDR0 groups may possess compensatory mechanisms that rescue or protect synapses
from toxicity in vivo which were not captured in our cell-culture based assay.
Interestingly, homogenates from CDR0+ individuals showed synaptotoxic activity that was
similar to that of homogenates from the CDR1 group and much worse than CDR0 normal
individuals, suggesting the AD-related synaptotoxic effect also occurs in CDR0+ individuals.
This result may be concordant with the findings of studies using 18F-Fludeoxyglucose Positron
Emission Tomography which indicated that loss of neuronal function could be detected
decades before the onset of AD [36]. The presence of synaptotoxic activity in CDR0+ individu-
als detected in our study potentially provides new evidence for pre-symptomatic cellular and
molecular pathophysiology, though it remains unclear whether these CDR0+ individuals have
preclinical AD or may also have compensatory factors that protect them from dementia. The
identified synaptotoxic effect in these unique individuals may provide new understanding of
the progression of AD and AD pathophysiology. On the other hand, we also found that
homogenates from CDR1 individuals showed a higher synaptotoxic activity than homogenates
from CDR3 cases, indicating the synaptotoxic effect is more active in early stage AD compared
with late stage AD.
The synaptotoxic effect of human brain homogenates seem independent of soluble Aβ and
tau. It is notable that numerous studies have demonstrated that soluble Aβ oligomers are the
main neurotoxic component in extracts from AD brain tissues [20–22, 37–39]. While most of
these studies focused on either synaptic plasticity (especially long-term potentiation) or neuro-
nal toxicity, our assay focused on the synaptic loss by measuring the number of pre-, post-,
and colocalized synapses before and after the treatment. On the other hand, in this study, we
aimed to use an unbiased screening approach to identify the potential Aβ dependent and Aβ
independent synaptotoxic substances in extracts from AD cases, cognitively normal individu-
als with AD pathology, and healthy controls. Therefore, instead of using previously identified
Aβ or tau enriched fractions, we used the whole tissue extracts and only separated by SEC in
‘Neurobasal Salt’ solution. It is possible that the amount of previously identified Aβ oligomers
in our final SEC fractioned samples was relatively low compared with previous studies and
therefore was below the detection limit of our assay. In addition, we only accessed soluble por-
tions of brain homogenates and, therefore, synaptotoxic activities associated with plaques,
Fig 6. Comparison of the number of colocalized puncta between raw and Aβ and tau immunodepleted brain
lysate fractions. (A, B) The efficiency of immunodepletion of Aβ and tau were evaluated by ELISA; (A) Sandwich
ELISA of Aβ showed almost complete removal of Aβ; (B) Indirect ELISA of tau in each fraction showed a complete
removal of tau in all fractions; (C) No significant difference in synaptotoxic activity was identified after
immunodepletion of Aβ or tau; immunodepletions of Aβ and tau slightly decreased the extent of synapse loss in
Fraction 16 to 21, however, the only significant different was that F20 in CDR3 homogenates showed reduced synapse
loss following immunodepletion of tau.
https://doi.org/10.1371/journal.pone.0259335.g006
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NFTs or other insoluble forms of Aβ and tau were not assessed. It is also possible that the spe-
cific epitopes of Aβ or tau responsible for synaptic toxicity are missing or protected by other
proteins that prevent them from immunodepletion. In fact, multiple forms of soluble Aβ or
tau may be present in SEC fraction with middle range molecular weight. For example, we (Fig
3B) and others [34] have identified anti-Aβ immunoreactive signals at relatively low levels in
the middle range SEC fractions. Meanwhile, both ELISA and Western blot studies using vari-
ous anti-tau antibodies showed different expression pattern between normal and AD subjects
(Fig 2E and 2F) [40, 41]. Preliminary results from our group have highlighted the heterogene-
ity and complexity of native structures of soluble Aβ aggregates [42]. Regardless of the exact
mechanisms, the dissociation between Aβ immunoreactivity from synaptotoxicity could hypo-
thetically be related to the failure of the majority of antibody based immunotherapies targeting
Aβ. Although many reasons have been put forward for the failure of these clinical trials [43],
there is increasing evidence to support doubts about whether Aβ is the primary cause of the
most common late onset, non-autosomal dominant forms of AD [44, 45].
Several limitations of this study should be noted. First, our assay measures synapses in a
chemical defined medium and may not reflect the in vivo conditions in brain including the
presence of astrocytes and microglia. Second, our assay focuses on the number of pre-, post-,
and colocalized synaptic puncta without the assessment of synaptic plasticity or other func-
tional activity. In fact, several studies have found that soluble tau aggregates [46], low molecu-
lar weight rather than high molecular weight Aβ oligomers [47], low molecular weight Aβ
oligomers and Aβ monomers [48] can inhibit synaptic plasticity. Third, although no to very lit-
tle immunoreactive Aβ or tau was left after immunodepletion, it is possible that certain modi-
fied or truncated Aβ or tau species or fragments may still remain in the samples. Extensive
immunodepletion of tau by a combination of different anti-tau antibodies is needed for future
studies. Fourth, as a pilot study for unbiased screening of synaptotoxic activities in control and
AD human brain homogenates, we have screened over several hundreds of SEC fractions,
however, the number of total subjects in each sample group was relatively small. Additional
studies involving a wider variety of brain samples from different brain regions will be impor-
tant. Fifth, the identified synaptotoxic activities could be artifactual. It is possible that synapto-
toxic substances were released during the homogenization and protein extraction of the
human brain tissue. To minimize potential artifacts, we used a Dounce tissue grinder to avoid
high-speed turbulence, mechanical shearing, and potential foaming from rotor style homoge-
nizers. Furthermore, compared with most previous studies that used PBS or TBS based buffers,
a ‘Neurobasal Salt’ buffer (see details in method section) was used in our study to provide a
more physiological condition as well as to minimize the introduction of extra salts and chemi-
cals to downstream culture assays. Finally, additional work beyond the scope of the current
communication will be required to identify the molecular natures of the synaptotoxic sub-
stances themselves.
In summary, we compared the synaptotoxic activities in SEC separated human frontal cor-
tex homogenates from normal, normal with AD pathology, early and late stage AD individuals.
Severe synaptotoxic activities were identified in CDR0+ and CDR1 samples, and the identified
synaptotoxic activities seemed independent to Aβ and tau. Our results from CDR0+ individu-
als provided a new understanding of the relationship between AD pathology and AD
pathogenesis.
Supporting information
S1 Fig. Scatterplots of individual levels Tau among control and AD patients. All values
were measured by indirect ELISA, all samples were measured triplicated. One-way ANOVA
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followed by Tukey’s multiple comparisons test were used for all measurements (��� p� 0.001,
� p� 0.05, error bar indicates S.D.). (A) Indirect ELISA using the HJ8.7 (anti-tau118-122
AAGHV [30]) antibody revealed significantly higher tau in the CDR0 group compared with
all AD pathology positive samples (F(3,25) = 3.751, p = 0.0237; CDR0 vs CDR0+: p = 0.0484,
CDR0 vs CDR1: p = 0.0005, and CDR0 vs CDR3: p = 0.0002); (B) No difference was found
when using the HJ9.3 (anti-tau589-598 GGKVQIINKK, [1]) antibody (F(3,25) = 1.004,
p = 0.4075; (C) Indirect ELISA using an anti-phosphorylated tau (phospho T205) antibody
revealed a significantly higher level in the CDR0 group compared with CDR1 (F(3,25) = 3.448,
p = 0.0318; CDR0 vs CDR1: p = 0.0408).
(TIF)
S2 Fig. Scatterplots of individual levels of synaptotoxic activities in each SEC fractions
from control and AD patient groups at 24 hours. Two-way ANOVA followed by Dunnett’s
multiple comparison test between CDR0 and other groups were used for all measurements
(���� p� 0.0001, ��� p� 0.001, �� p� 0.01, � p� 0.05, error bar indicates SEM) (A) Compari-
son of presynaptic VAMP2 synaptotoxic activities among control and AD patient groups at 24
hours; severe VAMP2 loss was found in wells incubated with lysate fractions 17 to 20; (B)
Comparison of postsynaptic PSD95 synaptotoxic activities among control and AD patient
groups at 24 hours. Loss of PSD95 post synaptic puncta was found in wells incubated with
lysate fractions 17 to 20. (C) Comparison of colocalized pre and post synaptic puncta among
control and AD patient groups at 24 hours; loss of colocalized synaptic puncta was found in
wells incubated with fractions 17 to 20.
(TIF)
S3 Fig. Scatterplots of individual levels of synaptotoxic activities in each SEC fractions
from control and AD case groups at 72 hours. Two-way ANOVA followed by Dunnett’s
multiple comparison test between CDR0 and other groups were used for all measurements
(���� p� 0.0001, ��� p� 0.001, �� p� 0.01, � p� 0.05, error bar indicates SEM) (A) Compari-
son of presynaptic VAMP2 synaptotoxic activities among control and AD case groups at 72
hours; significant VAMP2 loss were found in wells incubated with lysate fractions 17 to 20;
several fractions from CDR0+ and CDR1 showed statistically more VAMP2 loss than from
CDR0; (B) Comparison of postsynaptic PSD95 synaptotoxic activities among control and AD
case groups at 72 hours. Loss of PSD95 post synaptic puncta was found in wells incubated with
lysate fractions 17 to 20. Fraction 18 from CDR0+ and CDR1 brain homogenates caused more
PSD95 postsynapse loss than fraction 18 from CDR0 brains. Fraction 19 from CDR3 brain
homogenates caused more PSD95 postsynapse loss than fraction 19 from CDR brains. (C)
Comparison of colocalized pre and post synaptic puncta among control and AD case groups at
72 hours; loss of colocalized synaptic puncta were found in wells incubated with fractions 17 to
20. Fractions 17–19 from CDR0+ and CDR1 brain homogenates caused more colocalized syn-
aptic puncta loss than comparable fractions from CDR0 brains.
(TIF)
S4 Fig. Correlation of age and post-mortem interval with synaptotoxic activity. (A) Pearson
correlation coefficients was calculated between average synaptotoxic activities of SEC fraction
16 to 20 and the age of each subjects. No significant correlation was found between synapto-
toxic activities and the age of each subject with R2 = 0.0430 and p = 0.2804; (B) Pearson corre-
lation coefficients between synaptotoxic activities and post-mortem interval was also not
significant with R2 = 0.0436 and p = 0.2770.
(TIF)
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S1 Table. Adjusted P value of Tukey’s multiple comparisons test on synaptic puncta count
between sample groups at 72 hours.
(DOCX)
S2 Table. Adjusted P value of Tukey’s multiple comparisons test on synaptic puncta count
between sample groups at 24 hours.
(DOCX)
S3 Table. Adjusted P value of Dunnett’s multiple comparisons test on synaptic puncta
count between control and immunodepletion samples at 72 hours.
(DOCX)
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